首页> 外文期刊>Journal of lower genital tract disease. >Risk of cervical intraepithelial neoplasia 2+ among women with a history of previous treatment for cervical intraepithelial neoplasia: ASCUS and LSIL Pap smears after treatment.
【24h】

Risk of cervical intraepithelial neoplasia 2+ among women with a history of previous treatment for cervical intraepithelial neoplasia: ASCUS and LSIL Pap smears after treatment.

机译:有宫颈上皮内瘤变的既往治疗史的女性中,宫颈上皮内瘤变的风险为2+:治疗后ASCUS和LSIL子宫颈抹片检查。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The objective of the current study was to describe outcomes among women with low-grade abnormalities on cervical cytology screening in the setting of previous excisional or ablative treatment for cervical intraepithelial neoplasia (CIN). METHODS: Study participants were recruited into the Study to Understand Cervical Cancer Early Endpoints and Determinants. At enrollment, the patient's previous cytology results, previous colposcopic biopsy results, and previous cervical procedures were recorded. Study procedures included collection of biospecimens followed by colposcopy and biopsy. From clinical records, additional information regarding previous treatment for CIN was collected. RESULTS: Two hundred seventy-four women had an atypical squamous cells of uncertain significance (ASCUS) referral Pap and 532 women had a low-grade squamous intraepithelial lesion (LSIL) referral Pap. For patients with an ASCUS referral Pap, previous treatment was associated with an odds ratio for CIN 2+ (45.0% vs 28.2% of untreated patients) of 2.08 (95% confidence interval = 1.05-4.13, p = .04). For patients with an LSIL referral Pap, 33.3% of those women with previous treatment had CIN 2+ compared with 16.7% of those patients enrolled with no previous treatment (odds ratio = 2.49, 95% confidence interval = 1.12-5.51, p = .03). CONCLUSIONS: Patients with a history of previous treatment for CIN have a 2-fold risk of CIN 2+ at the time of colposcopy referral for ASCUS or LSIL cervical cytology.
机译:目的:本研究的目的是描述先前接受过切除或消融治疗宫颈上皮内瘤变(CIN)的宫颈细胞学筛查中低度异常女性的结局。方法:将研究参与者纳入研究以了解宫颈癌的早期终点和决定因素。入组时,记录患者先前的细胞学检查结果,先前的阴道镜活检结果和先前的宫颈检查程序。研究程序包括收集生物样本,然后进行阴道镜检查和活检。从临床记录中,收集了有关先前CIN治疗的其他信息。结果:274名妇女有非典型意义的鳞状上皮细胞转诊子宫颈癌(ASCUS),532名妇女有低度鳞状上皮内病变(LSIL)子宫颈癌转诊子宫颈癌。对于患有ASCUS推荐巴氏检查的患者,先前的治疗与CIN 2+的优势比(45.0%对比未治疗患者的28.2%)为2.08(95%置信区间= 1.05-4.13,p = .04)相关。对于使用LSIL推荐子宫颈癌的患者,之前接受过治疗的女性中有33.3%的患者具有CIN 2+,而之前没有接受过治疗的女性中有16.7%的患者具有CIN 2+(赔率= 2.49,95%的置信区间= 1.12-5.51,p =)。 03)。结论:先前有CIN治疗史的患者在ASCUS或LSIL宫颈细胞学转诊阴道镜时发生CIN 2+风险的2倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号